AMRC strikes deal to aid Russian antimicrobial research

Skolkovo hub (Courtesy of NetBUG [CC BY-SA 3.0])

The AMR Centre (AMRC) has teamed up (PDF) with Russia’s Skolkovo Foundation to further development of therapies that overcome microbial resistance. AMRC will provide preclinical support to startups working out of an incubator overseen by the foundation.

Skolkovo has succeeded in incubating a large number of biomedical startups. But its antimicrobial efforts are underdeveloped and cut off from international funding, shortcomings Skolkovo is looking to AMRC to help address.

“Out of our 430 biomedical startups, Skolkovo’s project portfolio includes only a few companies that are developing new antibiotics or diagnostic solutions in this therapeutic area and we would like to have more,” Kirill Kaem, SVP for innovations at the Skolkovo Foundation, said in a statement. “This partnership is an opportunity for innovative Russian companies to become a part of international research programs.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

As part of the $400 million, U.S. government backed CARB-X initiative, AMRC has access to sources of funding that could further research in Russia. AMRC plans to help Russian startups access these and other monies, while also making its R&D expertise available to the companies. 

RELATED: AMRC strikes deal to aid Russian antimicrobial research

The agreement with Skolkovo is part of a concerted effort by AMRC to form cross-border alliances. Recognizing that it is powerless to stop the rise of antimicrobial resistance itself, the U.K. has made international cooperation a focus of its efforts in the area since they took shape under an earlier government. AMRC expects these activities to continue next year.

“We are part of a number of U.K. government initiatives to build partnerships overseas and this will be a central part of our mission as we move into 2018,” AMRC executive director Peter Jackson said in a statement.

AMRC currently has two other international collaborations. The public-private partnership licensed metallo-beta-lactamase inhibitors from Sweden’s Medivir two months ago. And the month before that, it signed up to co-develop  Microbiotix's T3SS inhibitor program.

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.